Entering the first full trading hour of Wednesday's session, Madison Mills monitors several of the day's developing market ...

Novo Nordisk on Wednesday managed the unusual feat of seeing its stock price rise after reducing its earnings outlook. But ...

Pedersen and Maggie Fick COPENHAGEN/LONDON (Reuters) -Obesity drugmaker Novo Nordisk downgraded its 2025 sales forecast on ...

Investors are betting that Lilly will maintain its momentum. Its share price has climbed by a third since the start of 2024; Novo’s has fallen by as much (see chart 2). Lilly’s edge rests on a more ...

Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...

Eli Lilly won’t lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an ...

Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...

Novo Nordisk CFO Karsten Munk Knudsen speaks on Bloomberg Television about earnings, tariffs and the impact of compounding in ...

Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, cut its ...

Novo Nordisk, which also makes Wegovy, fell victim to 'compounding' - a practice in the US that allows pharmacies to produce ...

The FDA in February formally declared the end of the semaglutide shortage, which Novo Nordisk expects will help improve the ...

Obesity drugmaker Novo Nordisk has today downgraded its 2025 sales forecast, ending a four-year stretch of steady guidance ...